UCB (EBR:UCB) UCB Media Room: UCB and Ferring Pharmaceuticals agreement

Transparency directive : regulatory news

07/07/2020 19:00

https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb513= 9PTmAm2ORJ-2Fb7C-2B6eni22dDNGFB-2FIreUzrmiICun7MobCJN9eTEeafq3loaxbbNK7ig6C= MnuKrXTfRhq2y-2FPYTHnkzWaeyRH5RX9qNv8_mX_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVW= u7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9= g1wa997wZWoFMHYW1p3SWRVtkQ0cRgO-2BqdCJqf6hhft0KqmXgWh4iw-2F6GVJCRaIdxQ0EqJL= -2FknAXeFE-2F9hsXZp1blVV37mt-2FXSvpWJZLgm6VUQxrZQT-2FFOWbdZIjwoycC7Yi4Li4Xm= m95BG3IIBjobygmqwv3S0WLElTYhMoaRdvjT0xdIaV-2B7ji5yqWkXdE7kt3XvUUBOVYPoxivRC= HNW3WTUovrqFh2cPVlWqb5WuI95yZv4TF-2BpPn5qVrFzyrE1kU-3D ** UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA^=C2=AE (= certolizumab pegol) for the Treatment of Adults with Moderate to Severe Cro= hn=E2=80=99s Disease ------------------------------------------------------------ =C2=B7 Ferring joins with UCB to promote CIMZIA prefilled syringe for Crohn= =E2=80=99s disease in the U.S. =C2=B7 Co-promotion strengthens commitment to patients living with Crohn=E2= =80=99s disease by reaching more gastroenterologists while also continuing = patient support programs=C2=A0 =C2=B7 Ferring is expanding its focus in specialty areas within gastroenter= ology, demonstrating commitment to gut health=C2=A0 =C2=B7 UCB is preparing for future launches in immunology, demonstrating co= mmitment to patients with severe chronic diseases=C2=A0 Brussels, Belgium and Parsippany, USA =E2=80=93 July 7, 2020 (7:00 p.m. CET= and 1:00 p.m. ET) =E2=80=93 UCB and Ferring Pharmaceuticals Inc. today ann= ounced they have entered into a co-promotion agreement to commercialize the= prefilled syringe formulation of CIMZIA^=C2=AE (certolizumab pegol) in the= United States, specifically for the treatment of Crohn=E2=80=99s disease (= CD). Ferring will take over marketing, sales promotion, and field medical a= ffairs activities. UCB will continue to be responsible for all product-rela= ted activities, including revenue recognition. CIMZIA is an injectable biol= ogic treatment option for adults with moderate to severe Crohn=E2=80=99s di= sease with inadequate response to conventional therapy. UCB will continue t= o promote and to commercialize the lyophilized formulation of CIMZIA for al= l indications as well as the prefilled syringe formulation for CIMZIA=E2=80= =99s rheumatology and dermatology indications.=C2=A0 =E2=80=9CUCB is committed to serving the needs of immunology patients, incl= uding those living with Crohn=E2=80=99s disease. We are excited about this = opportunity as it will expand the awareness to the benefits of CIMZIA for i= ndividuals living with moderate to severe Crohn=E2=80=99s disease, while co= ntinuing to support patients through our services and programs,=E2=80=9D sa= id Camille Lee, Head of U.S. Immunology at UCB. =E2=80=9CWe believe UCB and= Ferring are a strategic fit for the co-promotion as both companies have a = strong patient-focused commitment and Ferring has expertise in gastroentero= logy. UCB is preparing for future launches in immunology, demonstrating our= commitment to patients with severe chronic diseases.=E2=80=9D This co-promotion allows Ferring to expand its growing portfolio in the gas= trointestinal space and support patients living with Crohn=E2=80=99s diseas= e, while enabling UCB to focus on and prepare for the future.=C2=A0 =E2=80=9CFerring is focusing on gut health as we expand our gastroenterolog= y portfolio,=E2=80=9D said Brent Ragans, President of Ferring US. =E2=80=9C= Together with our existing portfolio, this agreement with UCB will allow Fe= rring to offer treatment options to the nearly 800,000 adult patients in th= e U.S. who suffer from Crohn=E2=80=99s disease.=E2=80=9D CIMZIA has been a treatment option for adults living with moderate to sever= e Crohn=E2=80=99s disease over the last 12 years, since it was approved by = the FDA in 2008 based on safety and efficacy data from clinical trials in m= ore than 1,500 patients with Crohn's disease.=C2=A0 =C2=A0 CIMZIA can be administered either through self-injection or by a healthcare= professional.^1 CIMZIA can lower the ability to fight infections. Some peo= ple who received CIMZIA have developed serious infections, including tuberc= ulosis (TB) and infections caused by viruses, fungi, or bacteria that have = spread throughout the body.^1 Some of these serious infections have caused = hospitalization and death.^1 About Crohn=E2=80=99s disease=C2=A0 Crohn=E2=80=99s disease is an inflammatory bowel disease causing chronic in= flammation of the gastrointestinal (GI) tract.^2 Crohn=E2=80=99s disease ca= n affect any part of the GI tract from mouth to anus, most commonly involvi= ng the ileum and proximal colon.^3 It belongs to a group of conditions know= n as inflammatory bowel diseases, or IBD.^4 The disease can occur at any ag= e, but is most often diagnosed in adolescents and adults between the ages o= f 20 and 30.^2 Approximately 780,000 Americans are currently affected by Cr= ohn=E2=80=99s disease.^3 Patients with Crohn=E2=80=99s disease may present acutely or have a history= of symptoms prior to confirming diagnosis.^4 A hallmark symptom in patient= s with Crohn=E2=80=99s disease is abdominal pain.^4 Other symptoms include = diarrhea potentially persistent in nature, GI bleeding, urgent need to move= bowels, abdominal cramps, sensation of incomplete bowel evacuation and con= stipation, which can lead to bowel obstruction.^4 About CIMZIA^=C2=AE in the US CIMZIA is the only Fc-free, PEGylated anti-TNF (Tumor Necrosis Factor). CIM= ZIA has a high affinity for human TNF-alpha, selectively neutralizing the p= athophysiological effects of TNF-alpha. CIMZIA is indicated for reducing signs and symptoms of Crohn's disease (CD)= and maintaining clinical response in adult patients with moderately to sev= erely active disease who have had an inadequate response to conventional th= erapy. CIMZIA is also indicated for the treatment of adults with moderately to sev= erely active rheumatoid arthritis (RA), adults with active psoriatic arthri= tis (PsA), adults with active ankylosing spondylitis (AS), and adults with = active non-radiographic axial spondyloarthritis (nr-axSpA) with objective s= igns of inflammation. In addition, CIMZIA is indicated for the treatment of moderate to severe pl= aque psoriasis (PSO) in adults who are candidates for systemic therapy or p= hototherapy. See important safety information including risk of serious bac= terial, viral and fungal infections and tuberculosis below. IMPORTANT SAFETY INFORMATION about CIMZIA in the U.S.=C2=A0 CONTRAINDICATIONS CIMZIA is contraindicated in patients with a history of hypersensitivity re= action to certolizumab pegol or to any of the excipients. Reactions have in= cluded angioedema, anaphylaxis, serum sickness, and urticaria. SERIOUS INFECTIONS Patients treated with CIMZIA are at increased risk for developing serious i= nfections that may lead to hospitalization or death. Most patients who deve= loped these infections were taking concomitant immunosuppressants such as m= ethotrexate or corticosteroids. Discontinue CIMZIA if a patient develops a serious infection or sepsis. Reported infections include: =C2=B7 Active tuberculosis (TB), including reactivation of latent TB. Patie= nts with TB have frequently presented with disseminated or extrapulmonary d= isease. Test patients for latent TB before CIMZIA use and during therapy. I= nitiate treatment for latent TB prior to CIMZIA use. =C2=B7 Invasive fungal infections, including histoplasmosis, coccidioidomyc= osis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patien= ts with histoplasmosis or other invasive fungal infections may present with= disseminated, rather than localized, disease. Antigen and antibody testing= for histoplasmosis may be negative in some patients with active infection.= Consider empiric anti-fungal therapy in patients at risk for invasive fung= al infections who develop severe systemic illness. =C2=B7 Bacterial, viral, and other infections due to opportunistic pathogen= s, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with CIMZIA prior to= initiating therapy in the following patients: with chronic or recurrent in= fection; =C2=A0who have been exposed to TB; =C2=A0with a history of opportu= nistic infection; who resided in or traveled in regions where mycoses are e= ndemic; with underlying conditions that may predispose them to infection. M= onitor patients closely for the development of signs and symptoms of infect= ion during and after treatment with CIMZIA, including the possible developm= ent of TB in patients who tested negative for latent TB infection prior to = initiating therapy. =C2=B7 Do not start CIMZIA during an active infection, including localized = infections. =C2=B7 Patients older than 65 years, patients with co-morbid conditions, an= d/or patients taking concomitant immunosuppressants may be at greater risk = of infection. =C2=B7 If an infection develops, monitor carefully and initiate appropriate= therapy. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children= and adolescent patients treated with TNF blockers, of which CIMZIA is a me= mber. CIMZIA is not indicated for use in pediatric patients. =C2=B7 Consider the risks and benefits of CIMZIA treatment prior to initiat= ing or continuing therapy in a patient with known malignancy. =C2=B7 In clinical trials, more cases of malignancies were observed among C= IMZIA-treated patients compared to control patients. =C2=B7 In CIMZIA clinical trials, there was an approximately 2-fold higher = rate of lymphoma than expected in the general U.S. population. Patients wit= h rheumatoid arthritis, particularly those with highly active disease, are = at a higher risk of lymphoma than the general population. =C2=B7 Malignancies, some fatal, have been reported among children, adolesc= ents, and young adults being treated with TNF blockers. =C2=A0Approximately= half of the cases were lymphoma, while the rest were other types of malign= ancies, including rare types associated with immunosuppression and malignan= cies not usually seen in this patient population. =C2=B7 Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare= type of T-cell lymphoma, have been reported in patients treated with TNF b= lockers, including CIMZIA. These cases have had a very aggressive disease c= ourse and have been fatal. The majority of reported TNF blocker cases have = occurred in patients with Crohn=E2=80=99s disease or ulcerative colitis, an= d the majority were in adolescent and young adult males. =C2=A0Almost all o= f these patients had received treatment with azathioprine or 6-mercaptopuri= ne concomitantly with a TNF blocker at or prior to diagnosis. Carefully ass= ess the risks and benefits of treating with CIMZIA in these patient types. =C2=B7 Cases of acute and chronic leukemia were reported with TNF blocker u= se. HEART FAILURE =C2=B7 Worsening and new onset congestive heart failure (CHF) has been repo= rted with TNF blockers. Exercise caution and monitor carefully. HYPERSENSITIVITY =C2=B7 Angioedema, anaphylaxis, dyspnea, hypotension, rash, serum sickness,= and urticaria have been reported following CIMZIA administration. If a ser= ious allergic reaction occurs, stop CIMZIA and institute appropriate therap= y. =C2=A0The needle shield inside the removable cap of the CIMZIA prefilled= syringe contains a plastic derivative of natural rubber latex which may ca= use an allergic reaction in individuals sensitive to latex. HEPATITIS B VIRUS REACTIVATION =C2=B7 Use of TNF blockers, including CIMZIA, may increase the risk of reac= tivation of hepatitis B virus (HBV) in patients who are chronic carriers. S= ome cases have been fatal. =C2=B7 Test patients for HBV infection before initiating treatment with CIM= ZIA. =C2=B7 Exercise caution in patients who are carriers of HBV and monitor the= m before and during CIMZIA treatment. =C2=B7 Discontinue CIMZIA and begin antiviral therapy in patients who devel= op HBV reactivation. Exercise caution when resuming CIMZIA after HBV treatm= ent. NEUROLOGIC REACTIONS =C2=B7 TNF blockers, including CIMZIA, have been associated with rare cases= of new onset or exacerbation of central nervous system and peripheral demy= elinating diseases, including multiple sclerosis, seizure disorder, optic n= euritis, peripheral neuropathy, and Guillain-Barr=C3=A9 syndrome. HEMATOLOGIC REACTIONS =C2=B7 Rare reports of pancytopenia, including aplastic anemia, have been r= eported with TNF blockers. Medically significant cytopenia has been infrequ= ently reported with CIMZIA. =C2=B7 Consider stopping CIMZIA if significant hematologic abnormalities oc= cur. DRUG INTERACTIONS =C2=B7 Do not use CIMZIA in combination with other biological DMARDS. AUTOIMMUNITY =C2=B7 Treatment with CIMZIA may result in the formation of autoantibodies = and, rarely, in development of a lupus-like syndrome. Discontinue treatment= if symptoms of a lupus-like syndrome develop. IMMUNIZATIONS =C2=B7 Patients on CIMZIA should not receive live or live-attenuated vaccin= es. ADVERSE REACTIONS =C2=B7 The most common adverse reactions in CIMZIA clinical trials (=E2=89= =A58%) were: upper respiratory infections (18%), rash (9%), and urinary tra= ct infections (8%). For full prescribing information, please visit https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUZCWF= NIcc6axu1cq618NlczoNzixzR4-2FzA1T2OMu60OC8eKciWMV5vSACQevcg9ducyMl-2BW1vR03= EscsBmd8gvM-3DiyMF_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bS= l0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wa997wZWoFMHYW1p3SWR= VtkQ0cRgO-2BqdCJqf6hhft0KqmXgWh4iw-2F6GVJCRaIdxQ0EqJL-2FknAXeFE-2F9hsXZp1bl= VV37mt-2FXSvpWJZLgm6VUQ75xo3b4I-2FkEQUzkNtpxR-2FRTi3-2FZV5YdODu6DOtc2ys6tBM= ECYcuAr-2BbuhtTxdjGY-2BxiUt1PydeOh33uGBAmY5Ud4CScaLsA2YYe7tWb0GFkLrLA0j9Sni= rymWa5kS2c8YkQzzOuOGyo506hqb4OmQM-3D References:=C2=A0 1. CIMZIA^=C2=AE (certolizumab pegol) [package insert]. Smyrna, GA: UCB, In= c.=C2=A0 2. Crohn=E2=80=99s & Colitis Foundation. Living with Crohn=E2=80=99s Diseas= e. Available at: https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8= iDZJQyQ53jATUTn0z41-2FoGIT7scX-2FtWm9-2FYSvthmFzIfg-2BcugiHNtSUtAwmAXh0y8Hj= QEIZ8eU-2Bh-2BuQAkgb-2FE2hYYXES0SrIR67S0vFfRQySk7H4Etp4BeLHIvVxUY1TkskNd8ZQ= c0X4To9NN-2B1ljjiZ-2FHW-2F679Su1w-3DBeBR_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVW= u7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9= g1wa997wZWoFMHYW1p3SWRVtkQ0cRgO-2BqdCJqf6hhft0KqmXgWh4iw-2F6GVJCRaIdxQ0EqJL= -2FknAXeFE-2F9hsXZp1blVV37mt-2FXSvpWJZLgm6VUQ4fKJ32DjSRhzronPZmw8K-2FN84y9K= hxa2pZ9gGg3thjwIZbe-2FRPKlyexo6XNprKhlYuQvOo4NuWxAR4e-2FqDUsQb3sleAPdRy1VuN= sgMaUQCjtwrX8EtMG2xoCD34d4yWt-2FMTn-2BlpKuJmlIZGCDKI8E0-3D Last accessed: J= une 2020. 3. Crohn=E2=80=99s & Colitis Foundation. The Facts About Inflammatory Bowel= Diseases. November 2014. Available at: https://u7061146.ct.sendgrid.net/ls= /click?upn=3D4tNED-2FM8iDZJQyQ53jATUTn0z41-2FoGIT7scX-2FtWm9-2FYSvthmFzIfg-= 2BcugiHNtSUtAwmAXh0y8HjQEIZ8eU-2Bh-2Bngy5zTjjtykxEwnm530xPK9U-2FGWWZq2I9rhC= 2AF-2BZDB0IAr7zsdqvxG8HSzk7uvbw-3D-3DkXDv_xDPID0vOuylFAU8fv4e60wei4JxqEGBdV= Wu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c= 9g1wa997wZWoFMHYW1p3SWRVtkQ0cRgO-2BqdCJqf6hhft0KqmXgWh4iw-2F6GVJCRaIdxQ0EqJ= L-2FknAXeFE-2F9hsXZp1blVV37mt-2FXSvpWJZLgm6VUQ706NxYgbaxu8GYK55DDldgomlpep5= vgOQPjxBQMB0H6-2Bct5vJUp-2B4vfr9FcjjAf4NBovTPmrG2sxATjQDazTTiE6CcbX7QcEJp3J= mAOG1FeHeNQNpis4zpTgjW0C2sxtbI5e-2FLK4L1rCuY5sjo3b6g-3D Last accessed: June= 2020. 4. Crohn=E2=80=99s & Colitis Foundation. Overview of Crohn=E2=80=99s Diseas= e. Available at: https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8= iDZJQyQ53jATUTn0z41-2FoGIT7scX-2FtWm9-2FYSvthmFzIfg-2BcugiHNtSUtuYI2gY95N4d= PhaCD-2Fm3BN7s9iREJbCvHheVNl1VWme8-3DfL3F_xDPID0vOuylFAU8fv4e60wei4JxqEGBdV= Wu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c= 9g1wa997wZWoFMHYW1p3SWRVtkQ0cRgO-2BqdCJqf6hhft0KqmXgWh4iw-2F6GVJCRaIdxQ0EqJ= L-2FknAXeFE-2F9hsXZp1blVV37mt-2FXSvpWJZLgm6VUQwYqHK8bTASIeqkR1sEX-2Fy-2FVTP= LrO05h-2F2VDj53hjWbbiIvpvS4cdZsiUBsXSzIjdzwDA6ZmAUMnL5URi-2B84CMgERGRDwnXo2= elS1C5SJqvB-2BE6oaqThAKXp7Ica0HsPkgbZcUu4ogZaoTzvvDsDqf0-3D Last accessed: = June 2020. # # # CIMZIA^=C2=AE is a registered trademark of the UCB Group of Companies. For further information, Ferring Pharmaceuticals: Heather Guzzi =C2=A0=C2=A0 =C2=A0 Director, Brand Communications=C2=A0 (862) 286-5254 (direct) (973) 769-3999 (mobile) heather.guzzi@ferring.com For further information, UCB: Corporate Communications Laurent Schots=C2=A0 Media Relations, UCB =C2=A0 T+32.2.559.92.64 =C2=A0Laurent.schots@ucb.com=C2=A0 Investor Relations Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0 Investor Relations, UCB T +32.2.559.94.14, antje.witte@ucb.com=C2=A0 =C2=A0 Isabelle Ghellynck Investor Relations, UCB T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With more than 7 600 people in= approximately 40 countries, the company generated revenue of =E2=82=AC 4.9= billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow = us on Twitter: @UCB_news About Ferring Pharmaceuticals Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical g= roup committed to helping people around the world build families and live b= etter lives. In the United States, Ferring is a leader in reproductive medi= cine and maternal health, and in specialty areas within gastroenterology an= d orthopaedics. For more information, call 1-888-FERRING (1-888-337-7464); = visit www.FerringUSA.com Forward looking statements UCB This press release may contain forward-looking statements including, withou= t limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, = =E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends= =E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim= ates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccont= inue=E2=80=9D and similar expressions. These forward-looking statements are= based on current plans, estimates and beliefs of management. All statement= s, other than statements of historical facts, are statements that could be = deemed forward-looking statements, including estimates of revenues, operati= ng margins, capital expenditures, cash, other financial information, expect= ed legal, arbitration, political, regulatory or clinical results or practic= es and other such estimates and results. By their nature, such forward-look= ing statements are not guarantees of future performance and are subject to = known and unknown risks, uncertainties and assumptions which might cause th= e actual results, financial condition, performance or achievements of UCB, = or industry results, to differ materially from those that may be expressed = or implied by such forward-looking statements contained in this press relea= se. Important factors that could result in such differences include: the gl= obal spread and impact of COVID-19, changes in general economic, business a= nd competitive conditions, the inability to obtain necessary regulatory app= rovals or to obtain them on acceptable terms or within expected timing, cos= ts associated with research and development, changes in the prospects for p= roducts in the pipeline or under development by UCB, effects of future judi= cial decisions or governmental investigations, safety, quality, data integr= ity or manufacturing issues; potential or actual data security and data pri= vacy breaches, or disruptions of our information technology systems, produc= t liability claims, challenges to patent protection for products or product= candidates, competition from other products including biosimilars, changes= in laws or regulations, exchange rate fluctuations, changes or uncertainti= es in tax laws or the administration of such laws, and hiring and retention= of its employees. There is no guarantee that new product candidates will b= e discovered or identified in the pipeline, will progress to product approv= al or that new indications for existing products will be developed and appr= oved. Movement from concept to commercial product is uncertain; preclinical= results do not guarantee safety and efficacy of product candidates in huma= ns. So far, the complexity of the human body cannot be reproduced in comput= er models, cell culture systems or animal models. The length of the timing = to complete clinical trials and to get regulatory approval for product mark= eting has varied in the past and UCB expects similar unpredictability going= forward. Products or potential products which are the subject of partnersh= ips, joint ventures or licensing collaborations may be subject to differenc= es disputes between the partners or may prove to be not as safe, effective = or commercially successful as UCB may have believed at the start of such pa= rtnership. UCB=E2=80=99s efforts to acquire other products or companies and= to integrate the operations of such acquired companies may not be as succe= ssful as UCB may have believed at the moment of acquisition. Also, UCB or o= thers could discover safety, side effects or manufacturing problems with it= s products and/or devices after they are marketed. The discovery of signifi= cant problems with a product similar to one of UCB=E2=80=99s products that = implicate an entire class of products may have a material adverse effect on= sales of the entire class of affected products. Moreover, sales may be imp= acted by international and domestic trends toward managed care and health c= are cost containment, including pricing pressure, political and public scru= tiny, customer and prescriber patterns or practices, and the reimbursement = policies imposed by third-party payers as well as legislation affecting bio= pharmaceutical pricing and reimbursement activities and outcomes. Finally, = a breakdown, cyberattack or information security breach could compromise th= e confidentiality, integrity and availability of UCB=E2=80=99s data and sys= tems. Given these uncertainties, you should not place undue reliance on any of su= ch forward-looking statements. There can be no guarantee that the investiga= tional or approved products described in this press release will be submitt= ed or approved for sale or for any additional indications or labelling in a= ny market, or at any particular time, nor can there be any guarantee that s= uch products will be or will continue to be commercially successful in the = future. UCB is providing this information, including forward-looking statements, on= ly as of the date of this press release and it does not reflect any potenti= al impact from the evolving COVID-19 pandemic, unless indicated otherwise. = UCB is following the worldwide developments diligently to assess the financ= ial significance of this pandemic to UCB. UCB expressly disclaims any duty = to update any information contained in this press release, either to confir= m the actual results or to report or reflect any change in its forward-look= ing statements with regard thereto or any change in events, conditions or c= ircumstances on which any such statement is based, unless such statement is= required pursuant to applicable laws and regulations. Additionally, information contained in this document shall not constitute a= n offer to sell or the solicitation of an offer to buy any securities, nor = shall there be any offer, solicitation or sale of securities in any jurisdi= ction in which such offer, solicitation or sale would be unlawful prior to = the registration or qualification under the securities laws of such jurisdi= ction. GenericFile 070720 - FINAL Joint UCB Ferring Announcement Release - WITH LOGOS (https:/= /u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2= ORJ-2Fb7C-2B6eni22dDNGFB-2FIreUzrmiICuEilJQ9ejI8hhMOyogPOJR7Xb8ezcwR1v4dXQs= 1zaOMQ-3DU73G_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0Kxv= Ps6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wa997wZWoFMHYW1p3SWRVtkQ0= cRgO-2BqdCJqf6hhft0KqmXgWh4iw-2F6GVJCRaIdxQ0EqJL-2FknAXeFE-2F9hsXZp1blVV37m= t-2FXSvpWJZLgm6VUQxGeXXqWorKaIkYQEN1AtiHtGZDO4k5W7PuhC76AixMbgMXaJ0tCmmrwpS= 4uN6HonBdiMSLbccrLxkHJp5kWgfBtk8WHpSNNdcTDsUuAEfPZBQcl7lj4SUL0kcmk9bATtHKQ-= 2Bu6zO-2FHcjBhitQO-2Fonc-3D=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jAT= UeYfdhr1xEBQnaPhR2RKx1tfe2VKDZTewv5u80JomRcXtCbR1z7hcttTt2Uhka5nmskWFH2UoeA= lVmftBStnOM4OmK75JvBBlVuEiwxUruca3JlPgqUplNB1law1Ek-2BYL95s1QW2uNmRhrH-2Bja= 1cQK8-3Dyccb_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvP= s6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wa997wZWoFMHYW1p3SWRVtkQ0c= RgO-2BqdCJqf6hhft0KqmXgWh4iw-2F6GVJCRaIdxQ0EqJL-2FknAXeFE-2F9hsXZp1blVV37mt= -2FXSvpWJZLgm6VUQ1jZ3sVJa-2Bx2Nr8ZJ2K03FoAL-2F1bpSRFSZ8vLBUk8U1kbcmFBcOPKJv= HZxFc4CcElbNJg2m6-2Fo4izD7Ns7eIPqm3UP1Hl4yKkXesVlnOjp-2BCUVGyxQEw5lHwKpSfB9= MIPFUPnoEbEwO0aA0FGe2Dtd8-3D=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=

UCB's latest news

25/04/2024 18:00

UCB (EBR:UCB) UCB Media Room: UCB and Ferring Pharmaceuticals agreement

Transparency directive : regulatory news

UCB's latest news

Other stories